Quick Answer
UroGen Pharma Ltd. reported R&D Expense of $67.11 million for fiscal year 2025.
UroGen Pharma Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $67.11M | +17.4% |
| 2024 | $57.15M | +25.3% |
| 2023 | $45.61M | -13.8% |
| 2022 | $52.91M | +11.0% |
| 2021 | $47.64M | +0.7% |
| 2020 | $47.31M | -4.0% |
| 2019 | $49.30M | +33.5% |
| 2018 | $36.93M | +97.5% |
| 2017 | $18.70M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.01M | +23.4% | -25.9% |
| June 30, 2025 | $18.91M | +22.8% | -4.8% |
| March 31, 2025 | $19.87M | +28.2% | +75.0% |
| September 30, 2024 | $11.36M | +11.0% | -26.3% |
| June 30, 2024 | $15.40M | +33.0% | -0.6% |
| March 31, 2024 | $15.49M | +24.0% | +51.5% |
| September 30, 2023 | $10.23M | -21.9% | -11.7% |
| June 30, 2023 | $11.58M | -8.4% | -7.3% |
- UroGen Pharma Ltd. showed an increase of +17.4% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, UroGen Pharma Ltd.’s r&d expense has grown by 258.9% (from $18.70 million to $67.11 million).
- The most recent figure is from UroGen Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: